Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexinidazole vs NECT in Late-Stage HAT (T.b. gambiense)
NCT01685827Phase 3Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Oct 2012
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of Fexinidazole in human African trypanosomiasis (HAT), sponsored by Drugs for Neglected Diseases initiative. Started Oct 2012; status: completed.
02
Drugs
Fexinidazole
03
Conditions
human African trypanosomiasis (HAT)
Beyond the preview
Go deeper on NCT01685827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01685827.